Galapagos NV (Galapagos NV) Debt-to-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Debt-to-Asset?

Galapagos NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.1 Mil. Galapagos NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.4 Mil. Galapagos NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $4,751.8 Mil. Galapagos NV's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Galapagos NV Debt-to-Asset Historical Data

The historical data trend for Galapagos NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Debt-to-Asset Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.01	-	-	-	-

Competitive Comparison of Galapagos NV's Debt-to-Asset

For the Biotechnology subindustry, Galapagos NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Debt-to-Asset falls into.

Galapagos NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Galapagos NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.073	+	5.391)	/	4751.795
	=	0.00

Galapagos NV's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.073	+	5.391)	/	4751.795
	=	0.00

Galapagos NV (OTCPK:GLPGF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Galapagos NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

GLPG:USA GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.